🚨Primary Care🚨 #DHS2026: Challenging Evidence 🧠💊 📍 Melbourne | 📅 23–25 Oct @thedohertyinst.bsky.social ✔️ Primary care–focused sessions ✔️ Practical skills, cases & CPD ✔️ Global experts + real-world insights Bring #drugallergy #antibioticallergy into your practice. 👉 dhs2026.org @racgp.bsky.social

💊Drug Hypesensitivity Symposium 2026 - #DHS2026 Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026. Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social ➡️https://dhs2026.org/

Great #UTI session just starting in Hall A2-1. D Neofytos talking now, Barbara Trautner @bwtrautner.bsky.social up next. #ESCMIDGlobal2026 #IDSky #UTISky

So much fun! More coming 💕💯🏥🦠💉💊

▶️💥Tick tock, AMR clock: how should I treat my next ESBL bacteraemia patient? Excellent talk by Prof Tong Carbapenem sparing drug? Do we need it? Data? Does it increase CRE? Bayesian priori Next patient with ESBL : would you give pip tazo or Mero ? #ESCMIDGlobal2026 @steventong.bsky.social 👏 #idsky

Ring in the end of the year with our Breakpoints hosts and a review of all things IDWeek 2025! Join Drs. Erin McCreary, Julie Ann Justo, Whitney Buckel, and Ryan Moenster as they cover top abstracts and much more. BCIDP credit is available for this episode! Visit sidp.org/BCIDP for more information

The largest adult #penicillinallergy study ever undertaken - The iNAAN study @thedohertyinst.bsky.social @unimelb.bsky.social - 52 hospitals, 8 countries and over 5000 patients….Real world proof of the safety and effectiveness of inpatient DOC! Stay tuned #AMS folks 👀Results soon!

Is one dose ever enough? The PROSPECTOR 🪓 Trial will answer - A international double blind placebo controlled trial of 1 dose vs 5 day for #penicillinallergy. This week we recruited our 100th patient! 🎉 @thedohertyinst.bsky.social

👏CRE RESPOND is thrilled to announce the Sepsis: What is the Latest Data for Optimal Management of Sepsis seminar!👏 🗓️When: Thursday 16 October, 12pm-1pm (AEST) 🗺️Where: UQCCR (or online!) REGISTER HERE: bit.ly/3VBLeSx Don't miss out on the chance to hear from expert clinicians and researchers!

The whole team at CRE RESPOND are very proud of our very own Amy Legg on her graduation! Congratulations Amy!! 👏🎉 @leggwamy.bsky.social

Graduation nation! Huge thanks to the supers @gurujosh.bsky.social @steventong.bsky.social Jane Davies, Jason Roberts. Look after your kidneys guys!

🤩Dr Andrew Burke's recent presentation on 'Therapeutic Drug Monitoring in Non-Tuberculous Mycobacteria' was not one to miss... 📢Luckily, even if you weren't able to attend the Respiratory Infections seminar, you won't have to! youtu.be/V2nITG_rxp8?...

Congratulations Elise Mitri from NACE, Austin Health & The Peter Doherty Institute presenting the iNAAN Trial results - > 5000 pts & 1500 inpatient #penicillinallergy DOC performed. Safe irrespective of stakeholder with significant prescribing gains. Largest inpatient penicillin allergy study 👏🎉

On 7 August 2025, we will be hosting our Worldwide Precision Dosing seminar for the fifth year!💉 📢Chaired by Dr Amy Legg, a clinical pharmacist at RBWH, this event explores individualised drug therapy. To find out more about this event and register: bit.ly/3GtrIUb @leggwamy.bsky.social #UQCCR

Always happy to celebrate you @minyonavent.bsky.social ❤️ what a packet of legends

✨Hello and welcome to the official CRE Respond page!✨ CRE RESPOND aims to reduce the burden of antimicrobial resistance through optimal personalised dosing. 💊 🚨Follow us to stay up to date with our educational events and the latest goings-on in the world of anti-microbial optimisation! #uqccr

Congrats to @elisemitri.bsky.social, @trubianojason.bsky.social et al for their great work on safely delabeling patients with #penicillinallergy. Elise presenting their prospective, pharmacist-led program live at #ESCMIDGlobal #IDSky #PharmSky #openacess www.cmi-comms.com/article/S295...

#SNAPtrial will answer this question in a large RCT (rather than observational). Come to ESCMID global and hear the results!

Approaching more than all previous SAB trials combined! What next?!

Interested in PK modelling? CRE RESPOND is running its Population Pharmacokinetics workshop, from fundamentals to clinical practice. Much more practical program this year! Be quick spaces are limited. Register here: bit.ly/3ElRmJ6

Really excited by this article from @idpharmacometrx.bsky.social et al. Protamine as the prototype for megalin blockade to reduce/delay kidney accumulation of vanc (and maybe colistin and aminoglycosides…). But also an excellent VIKI overview, fab pics 💕 journals.asm.org/doi/10.1128/...

I learnt to name studies from the best!

🆕💫Retrospective cohort study #CMI AKI is a frequent complication of S. aureus bacteraemia and is associated with 30-day mortality Not “a cute” complication: phenotypic analysis of acute kidney injury in S. aureus bacteraemia #idsky #EMIMCC www.clinicalmicrobiologyandinfection.com/article/S119...

**Starting 2025 with a key update: The new ATS/CDC/ERS/IDSA guidelines on treating drug-susceptible and drug-resistant tuberculosis (TB) are out! What do you think about these changes? How will they shape clinical practice moving forward?** #idsky #tbsky #EMIMCC

Pharmacodynamic studies indicate that anaerobic killing is optimized when the plasma AUC) to MIC ratio is ≥70:1; the probability of achieving this target with 1000mg/d of metronidazole is > 99% against B. fragilis that exhibit MICs < 2mg/L #idsky #medsky #EMIMCC

🆕🔥Retrospective, multicenter, inverse probability-of-treatment weighted cohort study Among hospitalized patients with septic shock, there was no difference between cefepime and piperacillin-tazobactam on the occurrence of severe AKI #idsky #medsky academic.oup.com/cid/advance-...

Just in case you missed it Dr Emily Heil and Dr Julie Ann Justo with the greatest overview of aminoglycoside dosing for #UQCCR earlier this year! All the recordings here cre-respond.centre.uq.edu.au/event/sessio...